InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a note issued to investors on Tuesday. The firm set a "sell" rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research report on Wednesday, December 11th. They set a "buy" rating and a $5.00 price target on the stock.

InspireMD Stock Performance

NSPR traded up $0.22 during trading on Tuesday, reaching $2.94. 23,768 shares of the company's stock were exchanged, compared to its average volume of 32,571. The company's fifty day moving average price is $2.80 and its 200-day moving average price is $2.72. The firm has a market capitalization of $76.68 million, a PE ratio of -3.92 and a beta of 0.99. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42.

InspireMD (NYSE:NSPR - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million for the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter last year, the business earned ($0.15) earnings per share. Research analysts forecast that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Affiance Financial LLC lifted its holdings in InspireMD, Inc. (NYSE:NSPR - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 189,122 shares of the company's stock after purchasing an additional 5,376 shares during the quarter. Affiance Financial LLC owned 0.73% of InspireMD worth $497,000 as of its most recent SEC filing. Institutional investors own 44.78% of the company's stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.